Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He recently completed a Master’s degree in communications at Georgetown University.

Latest Posts

BIO Investor Forum’s Impressive Program Lineup

BIO Investor Forum

This week, BIO announced the final program and speakers for the 14th Annual BIO Investor Forum, an international investor forum which explores investment trends and opportunities in life sciences.  The event focuses on early and mid-stage private as well as emerging public companies that are poised for growth in 2016. The event will take place October 20-21, 2015, at the Parc 55 in San Francisco, California. “This year’s BIO Investor Forum features a compelling and Read More >

Events  |  Leave a comment  |  Email This Post

Wall Street Journal: The Assault on Drug Innovation


Today, the Wall Street Journal published an editorial commenting on yesterday’s proposed plan by Secretary Hillary Clinton’s campaign to dramatically increase intrusive government regulation of our industry. BIO shared many of the concerns raised by this editorial, concerns which were noted in our statement yesterday. To put into perspective the potential consequences of that proposal, the editorial noted as an example that “Inside of a decade or two, metastatic cancer may become a chronic condition and chemotherapy a relic.” Breakthroughs Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Statement on Patient Access to Medicines

“As a general policy, BIO does not comment on matters related to individual company products or product pricing decisions, such as today’s news about Turing Pharmaceuticals. That said, the focus of the biotechnology industry is to develop innovative therapies and cures for patients. This means it is imperative not only that we develop these new medicines, but that all patients have access to them, as necessary to meet their healthcare needs. This principle should apply Read More >

Health  |  Leave a comment  |  Email This Post

Share your Cutting Edge Ideas at the 2016 BIO International Convention

San Francisco, California

After a record-breaking event this year in Philadelphia, the BIO International Convention will return to San Francisco, California in 2016 with its sights set on creating another historic industry event. BIO is seeking cutting edge, engaging, and thought-provoking session ideas and prospective speakers for BIO 2016, which will be held June 6-9, 2016 in San Francisco. “We are planning to make this year’s event our best Convention ever by providing attendees with the education and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Reality Check for AHIP: Competition Driving Down Costs for Hepatitis C Meds


Yesterday at a House Judiciary Committee hearing on competition in the healthcare marketplace, AHIP Executive Vice President Daniel Durham took the occasion to bemoan what he termed “monopoly pricing” in the pharmaceutical industry. He proceeded to cite the cost of two new specialty medicines for Hepatitis C, Gilead Sciences’ Sovaldi and Harvoni, as a “case study” of that problematic monopoly pricing. Durham’s analysis suffers from a particularly egregious flaw: Gilead and its products do not enjoy Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,